Prediction of Multi-Target Networks of Neuroprotective Compounds with Entropy Indices and Synthesis, Assay, and Theoretical Study of New Asymmetric 1,2-Rasagiline Carbamates

Francisco J. Romero Durán 1, Nerea Alonso 1, Olga Caamaño 1, Xerardo García-Mera 1,* Matilde Yañez 2, Francisco J. Prado-Prado 1,3 and Humberto González-Díaz 4,5,*

1 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain; E-Mails: fcojavier.romero@rai.usc.es (F.J.R.D.); nerea.alonso@rai.usc.es (N.A.); molga.caamano@usc.es (O.C.); fprado@uqroo.mx (F.J.P.-P.)
2 Department of Pharmacology, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain; E-Mail: matilde.yanez@usc.es
3 Biomedical Sciences Department, Health Sciences Division, University of Quintana Roo (UQROO), Chetumal 77039, Mexico
4 Department of Organic Chemistry II, Faculty of Science and Technology, University of the Basque Country UPV/EHU, Leioa 48940, Spain
5 IKERBASQUE, Basque Foundation for Science, Bilbao 48011, Spain

* Authors to whom correspondence should be addressed;
E-Mails: xerardo.garcia@usc.es (X.G.-M.); humberto.gonzalezdiaz@ehu.es (H.G.-D.);
Tel.: +34-946-013-547 (H.G.-D.); Fax: +34-946-012-748 (H.G.-D.).

Received: 11 March 2014; in revised form: 19 August 2014 / Accepted: 21 August 2014 / Published: 24 September 2014

Abstract: In a multi-target complex network, the links (Lij) represent the interactions between the drug (di) and the target (tj), characterized by different experimental measures (Ki, Km, IC50, etc.) obtained in pharmacological assays under diverse boundary conditions (ci). In this work, we handle Shannon entropy measures for developing a model encompassing a multi-target network of neuroprotective/neurotoxic compounds reported in the CHEMBL database. The model predicts correctly >8300 experimental outcomes with Accuracy, Specificity, and Sensitivity above 80%–90% on training and external validation series. Indeed, the model can calculate different outcomes for >30 experimental measures in >400 different experimental protocols in relation with >150 molecular and cellular
targets on 11 different organisms (including human). Hereafter, we reported by the first
time the synthesis, characterization, and experimental assays of a new series of chiral
1,2-rasagiline carbamate derivatives not reported in previous works. The experimental tests
included: (1) assay in absence of neurotoxic agents; (2) in the presence of glutamate; and
(3) in the presence of H₂O₂. Lastly, we used the new Assessing Links with Moving
Averages (ALMA)-entropy model to predict possible outcomes for the new compounds in
a high number of pharmacological tests not carried out experimentally.

**Keywords:** CHEMBL; neuroprotective agents; rasagiline derivatives; asymmetric
synthesis; multi-target drugs; molecular information measures; Shannon entropy;
Markov chains; moving averages

1. Introduction

Entropy measures are universal parameters useful to codify biologically relevant information in
many systems. In the 1970’s Bonchev and Trinajstic *et al.* published works about the use of Shannon’s
entropy to calculate a structural information parameter [1–4]. Kier published another seminar works on
the use of Shannon’s entropy to encoding molecular structure in Cheminformatics studies in 1980 [4].
Many other authors used Shannon’s entropy parameters for the same purpose on small molecule
structure [5–10]. Graham *et al.* [11–16] used entropy measures to study the information properties
of organic molecules. Entropy information measures were used to describe proteins [17,18],
DNA sequences [19], protein networks [20], and magnetic resonance outcomes [21]. The software
MARCH-INSIDE (MI) uses the theory of Markov chains to calculate the parameters \( \theta_k(G) \). These
values are the Shannon entropies of order \( k^{th} \) of a graph \( G \). The \( \theta_k(G) \) values are useful quantify
information about the structure of molecular systems [22]. The graph \( G \) represents a complex
molecular system as a network of nodes interconnected by links \( (L_{ij} = 1) \) or not connected \( (L_{ij} = 0) \).
MI algorithm associates a Markov matrix to the graph \( G \) in order to define the probabilities of
interactions (ties or relationships) between nodes. These entropy parameters \( \theta_k(G) \) can be calculated
for many types of systems (molecular or otherwise). We have studied small molecules, RNA
secondary structures, protein sequences, viral surfaces, cerebral cortex networks, metabolic networks,
host-parasite networks, world trading networks, social networks, etc. In molecules, we know the
information about links \( L_{ij} \) (covalent bonds, hydrogen bonds, spatial contacts, etc.) beyond any
reasonable doubt. However, we can use the information (\( \theta_k(G) \) values)of the system to predict
interactions with other systems in a network of a higher-structural level. For instance, we use the \( \theta_k(G) \) values of drugs and targets structure to predict drug–target interactions (links) in drug–target network.
In other cases, linking patterns change, are not known, or we find contradictory information. This is
the case of the existence of different relationships between nodes in biological webs or social
networks. In these cases, we can use the \( \theta_k(G) \) values of known networks to find models useful to
predict links in new networks [23–25].

On the other hand, the discovery of new drugs for the treatment of neurodegenerative diseases such
as Alzheimer’s, Parkison’s, and Huntington’s disease, Friedreich ataxia and others, is an important
goal of medicinal chemistry [26–29]. The genes causing hereditary forms of some of these diseases have been identified but the molecular mechanisms of the neuronal degeneration have not been totally understood yet [30]. This picture, and some disappointing results in clinical trials, makes interesting the prediction of drug candidates with computational techniques [31,32]. In order to design these computational models we need to process chemical information from public databases. These databases have accumulated immense datasets of experimental results of pharmacological trials for many compounds. For instance, CHEMBL [33,34] is one of the biggest with more than 11,420,000 activity data for >1,295,500 compounds, and 9844 targets. This huge amount of information offers a fertile field for the application of computational techniques [34,35].

The analysis of all this data is very complex due to the presence of multi-target, multi-output, and multi-scale information. Multi-target complication emerges due to the existence of compounds with multiple targets [36–38]. This led to the formation of complex networks of drug–target interactions. We can represent drug–target networks as a graph with two types of nodes drugs (di) and targets (tj) interconnected by links (Li). Barabasi et al. [39], constructed a drug–target network based on Food and Drug Administration (FDA) drugs and proteins linked by drug–target binary associations. Csermely et al. [40], reviewed the use of networks, including drug–target networks, for drug discovery.

Multi-output feature refers to the necessity of prediction of different experimental parameters (IC50, Ki, Km, etc.) to decided whether two nodes (drug and target) interact (Lij = 1) or not (Lij = 0). Multi-scaling refers to the different structural levels of the organization of matter. In this case, the input variables quantify molecular information (drugs structure) and macromolecular information (targets). They have to quantify also cellular (cellular targets) and organism information (specie that express the target). In these models we have a high number of assays carried out in very different conditions (cq) like time, concentrations, temperature, cellular targets, tissues, organisms, etc. In a recent work, we combined the θk(G) values calculated with MI and the idea of Moving Average (MA) operators with a similar purpose [41]. In time series analysis the MA operators are average values of characteristic of the system for different seasons. In fact, MA models became popular after the initial works of Box and Jenkins [42]. In time series analysis, MA models may combine other operators I = Integrated, AR = Autoregressive, N = Non-linear operators, or X = Exogenous effects. In this sense, others models have emerged combining different operators: ARMA, ARIMA, VARIMA, ARIMAX, NARMA, etc. In multi-output modeling, we calculate the MA operators as the average of the property of the system (molecular descriptors or others) for all drugs or targets with a specific response in one assay carry out under a sub-set of conditions (cq). Consequently, our MA operator is not acting over a time domain but over a sub-set of conditions of the pharmacological assays. The idea of application of MA operators to other domains different from time is gaining adepts due to its advantages. For instance, Botella-Rocamora et al. [43] developed a model for disease mapping using spatial Box–Jenkins operators with the form of MAs, to define dependence of the risk of a disease to occur. In our models, we use MA in relation with properties of nodes of networks (drugs, proteins, reactions, laws, neurons, etc.); which form links Lij(cq) in specific sub-set of conditions (cq). For this reason, we decided to call this strategy as ALMA (Assessing Links with Moving Averages) models. Speck-Planche and Cordeiro reported different multi-target or multi-output models using the same type of ALMA models [44–46].
In the specific area of neurodegenerative diseases, almost all these datasets include also large sub-sets of assays involving potential neuroprotective drugs, targets, as well as drug-target and/or target–target interactions. The database NeuroDNet has interactive tools to create interaction networks for twelve neurodegenerative diseases. According to Vasaikar et al. [47], it is the first of its kind, which enables the construction and analysis of neurodegenerative diseases through protein interaction networks, regulatory networks and Boolean networks. In the case of neuroprotective compounds, some authors have reported multi-target ALMA models. García et al. used topological descriptors for a large series of 3370 active/non-active compounds to fit a classification function that can predict links $L_{ij}$ (interactions) of heterogeneous series of GSK inhibitors compounds with different neurological targets relevant to Alzheimer’s disease and parasite species. Speck-Planche et al. [48], developed a multi-target model using a large and heterogeneous database of inhibitors against five proteins associated with Alzheimer’s disease. The model correctly classified more than 90% of active and inactive compounds in the treatment of Alzheimer’s disease on both, training and prediction series. Several guidelines are offered in other paper to show how the use of fragment-based descriptors can be determinant for the design of multi-target inhibitors of proteins associated with Alzheimer’s disease [49].

In a recent work, we used the method TOPS-MODE (TM) [50] to calculate the structural parameters of drugs. The model correctly classified 4393 out of 4915 total cases with Specificity (Sp), Accuracy (Ac), and Sensitivity (Sn), of 80%–98%. We also used the method TM to develop one ALMA [51] model useful for the prediction of neuroprotective drugs. This dataset includes Multi-output assay endpoints of 2217 compounds for at least one out of 338 assays, with 148 molecular or cellular targets, and 35 types of activity measures in 11 model organisms (including human). In a third work [52], we introduced another ALMA model for neurotoxicity/neuroprotective effects of drugs based on the method MI. First, we used MI to calculate molecular descriptors of the type of stochastic spectral moments of all compounds. Next, we found a model that classified correctly 2955/3548 total cases on training and validation series with Ac, Sn, and Sp > 80%. Each data point (>8000) contains the values of 37 possible measures of activity, 493 assays, 169 molecular or cellular targets, and 11 different organisms (including human) for a given compound. The model has shown excellent results also in computational simulations of high-throughput screening experiments, with Ac = 90.6% for 4671 positive cases. Both models are able to predict the links $L_{ij}(a_q)$ between $i^{th}$ drugs and $j^{th}$ targets according to the assay $a_q$. However, we do not carried out a formal construction and a comparison of the drug-target networks for the CHEMBL data in previous papers. In any case, despite the high versatility of entropy measures to codify structural information, there is no report of a multi-target model for drug–target interactions for compounds with neuroprotective/neurotoxic effect. In this work, we report the first multi-target, multi-output, and multi-scale ALMA model for CHEMBL data of neuroprotective/neurotoxic effect of drugs. Then, we construct and compare for the first time three Multi-output assay complex networks for these CHEMBL dataset using the two previous models and the model reported in this work. From there, we reported by the first time the synthesis, characterization, and experimental assays of a new series of rasagiline carbamate derivatives not reported in previous works. We carried out three different experimental tests: assay (1) in absence of neurotoxic agents; (2) in the presence of glutamate; and (3) in the presence of $H_2O_2$. Finally, we used the new entropy model to predict possible outcomes for these compounds in a high number of pharmacological tests not carried out experimentally. The results presented here show the high
potential of entropy parameters of chemical information for the design of neuroprotective drugs, the construction of complex bio-molecular networks, and the potential of ALMA models for multi-target, multi-output, and multi-scale modeling.

2. Results and Discussion

2.1. Development of New Model for Prediction of Drug–Target Networks

2.1.1. Model Training and Validation

We report a model to predicting when the \(i^{th}\) compound may present a high (\(L_{ij}(c_q) = 1\)) or not (\(L_{ij}(c_q) = 0\)) value of the experimental parameter used to characterize interaction with a molecular or cellular target involved in a neuroprotective/neurodegenerative process. The output \(S_{ij}(c_q)\) of our multi-output model depend on both chemical structure of the \(i^{th}\) drug \(d_i\) and the set of conditions selected to perform the biological assay (\(c_q\)) including the \(j^{th}\) target, of course. In consonance, the ALMA model should predict different probabilities if we change the organisms (\(c_1\)), the biological assays (\(c_2\)), the molecular/cellular target (\(c_3\)), or the standard experimental parameter measured (\(c_4\)), for the same compound [53]. The best ALMA-entropy model found in this work was:

\[
S_i \left( c_q \right) = 1.1396 - 0.4039 \cdot p(c_i) \theta_1^i + 0.1993 \Delta \theta_1 \left( s_i \right) + 0.4349 \Delta \theta_1 \left( a_u \right) - 0.0202 \Delta \theta_1 \left( a_j \right) - 0.0017 \Delta \theta_1 \left( t_e \right) \\
N = 2661 \quad R_c = 0.72 \quad \chi^2 = 1913.007 \quad p < 0.005
\] (1)

The statistical parameters for the above equation in training are: Number of cases used to train the model (\(N\)), Canonical Regression Coefficient (\(R_c\)), Chi-square (\(\chi^2\)), and \(p\)-level [54]. The probability cut-off for this Linear Discriminant Analysis (LDA) model is \(p_1(c_q) > 0.5 \geq L_{ij}(c_q) = 1\). It means that the drug \(d_i\) predicted by the model, with probability \(p > 0.5\), is expected to give a positive outcome in the \(q^{th}\) assays carry out under the given set of conditions \(c_q\). This ALMA-entropy model presents excellent performance in both training and external validation series with Sn, Sp, and Ac > 80% (see Table 1). Values higher than 75% are acceptable for LDA-QSAR models, according to previous reports [55–59].

The first term in the equation, quantify both the quality of the input data \(p(c_i)\) and the information \(\theta_1^i\) about the structure of the drug (see material and methods and previous works [51]). We can expand the Box–Jenkins MA terms in the ALMA equation in order to clearly depict all the parameters involved:

\[
S_i \left( c_q \right) = 1.139556 - 0.403994 \cdot p_i(s_i) \theta_1^i + 0.199322 \left[ \theta_1^i \left( s_i \right) - p_i(s_i) \langle \theta_1^i \left( s_i \right) \rangle \right] + 0.434889 \left[ \theta_1^i \left( a_u \right) - p_i(a_u) \langle \theta_1^i \left( a_u \right) \rangle \right] - 0.020189 \left[ \theta_1^i \left( a_j \right) - p_i(a_j) \langle \theta_1^i \left( a_j \right) \rangle \right] - 0.001660 \left[ \theta_1^i \left( t_e \right) - p_i(t_e) \langle \theta_1^i \left( t_e \right) \rangle \right] \\
N = 2661 \quad R_c = 0.72 \quad \chi^2 = 1913.007 \quad p < 0.005
\] (2)
After inspection of this equation, we can see that the ALMA model can predict for the same compound different scores for different experimental parameters, targets, assays, or even different organisms. In Table 2 we illustrate the values of probability of drug–target interaction \( p_{ij}(c_q) \) predicted with the previous model, for several examples of known drugs or new promising compounds. These are the probabilities with which the \( i^{th} \) compound interact with the \( j^{th} \) drug under the assay conditions \( c_q \). This is equivalent to \( p_{ij}(c_q) > 0.5 \geq L_{ij}(c_q)_{\text{pred}} = 1 \). However, online supplementary material files contain a complete list with many examples of positive and control cases.

**Table 1.** Results of Assessing Links with Moving Averages (ALMA) models for entropy measures vs. different spectral moments.

| Descriptor     | Sub-Set | Stat. | %     | Groups                     | \( C_{ij}(m_j)_{\text{pred}} = 1 \) | \( C_{ij}(m_j)_{\text{pred}} = 0 \) | Reference |
|----------------|---------|-------|-------|----------------------------|-----------------------------------|-----------------------------------|-----------|
| MI-Entropy     | Train   | Sp    | 79.0  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 1092                              | 290                               | This work |
|                |         | Sn    | 91.5  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 412                               | 4438                              |           |
|                |         | Ac    | 88.7  | Total                               |                                    |                                    |           |
| MI spectral    | CV      | Sp    | 81.3  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 379                               | 87                                | [52]      |
| moments        |         | Sn    | 92.6  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 119                               | 1492                              |           |
|                |         | Ac    | 90.1  | Total                               |                                    |                                    |           |
| TM spectral    | Train   | Sp    | 84.6  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 1172                              | 214                               | [51]      |
| moments        |         | Sn    | 82.4  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 224                               | 1051                              |           |
|                |         | Ac    | 83.5  | Total                               |                                    |                                    |           |
|                | CV      | Sp    | 83.3  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 385                               | 77                                |           |
|                |         | Sn    | 81.6  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 78                                | 347                               |           |
|                |         | Ac    | 82.5  | Total                               |                                    |                                    |           |
|                | Train   | Sp    | 81.3  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 1533                              | 352                               |           |
| TM spectral    |         | Sn    | 98.0  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 36                                | 1762                              |           |
| moments        |         | Ac    | 89.5  | Total                               |                                    |                                    |           |
|                | CV      | Sp    | 81.0  | \( L_{ij}(C_q)_{\text{obs}} = 1 \) | 513                               | 120                               |           |
|                |         | Sn    | 97.7  | \( L_{ij}(C_q)_{\text{obs}} = 0 \) | 14                                | 585                               |           |
|                |         | Ac    | 89.1  | Total                               |                                    |                                    |           |

MI, MARCH-INSIDE; \(^\text{a}\) Sensitivity = Sn = Positive Correct/Positive Total; Specificity = Sp = Negative Correct/Negative Total; Accuracy = Ac = Total Correct/Total; TM, TOPS-MODE.

**Table 2.** Examples predicted with the model.

| Compound (i) | \( p_{ij}(c_q) \) | Assay ID | Measure (Units) | Organism | Target Protein |
|--------------|--------------------|----------|-----------------|----------|----------------|
| Arecoline    | 0.94               | 796814   | Efficiency (%)  | rno      | Muscarinic acetylcholine receptor |
| Bipinnatin-A | 1.00               | 751272   | Inhibition (%)  | mmu      | Acetylcholine receptor protein β chain |
| Carachol     | 0.99               | 796814   | Efficiency (%)  | rno      | Muscarinic acetylcholine receptor |
| Caulophylline| 0.96               | 838016   | EC\(_{50}\) (nM) | hsa      | Neuronal acetylcholine receptor; α4/β2 |
| Citalopram   | 0.99               | 740208   | \( K_i \) (nM)  | mmu      | Dopamine transporter |
| Condelphine  | 1.00               | 748943   | −\log(\text{IC}_{50}) (nM) | rno      | Neuronal acetylcholine receptor protein α-7 subunit |
| Compound (i)     | $p_i(c_q)$ | Assay ID | Measure (Units) | Organism | Target Protein                                                                 |
|-----------------|-----------|----------|-----------------|----------|--------------------------------------------------------------------------------|
| Delcorine       | 1.00      | 748943   | $-\log(IC_{50})$ (nM) | rno      | Neuronal acetylcholine receptor protein $\alpha$-7 subunit                     |
| Delsoline       | 1.00      | 748943   | $-\log(IC_{50})$ (nM) | rno      | Neuronal acetylcholine receptor protein $\alpha$-7 subunit                     |
| Desipramine     | 0.99      | 797692   | $-\log(IC_{50})$ (nM) | rno      | Norepinephrine transporter                                                     |
| Elatine         | 1.00      | 748943   | $-\log(IC_{50})$ (nM) | rno      | Neuronal acetylcholine receptor protein $\alpha$-7 subunit                     |
| Emopamil        | 1.00      | 817225   | $-\log(IC_{50})$ (nM) | rno      | Voltage-gated R-type calcium channel $\alpha$-1E subunit                      |
| Epibatidine     | 0.94      | 838016   | EC$_{50}$ (nM)    | hsa      | Neuronal acetylcholine receptor; $\alpha$4/$\beta$2                          |
| Epibatidine     | 0.19      | 825420   | Efficacy (%)      | hsa      | Neuronal acetylcholine receptor; $\alpha$4/$\beta$2                          |
| Femoxetine      | 0.99      | 740206   | $K_i$ (nM)        | mmu      | Dopamine transporter                                                           |
| Femoxetine      | 0.99      | 740207   | $K_i$ (nM)        | mmu      | Norepinephrine transporter                                                     |
| Femoxetine      | 0.99      | 740208   | $K_i$ (nM)        | mmu      | Dopamine transporter                                                           |
| Fisetin         | 0.05      | 1027709  | %max (%)          | mmu      | HT22 cells                                                                     |
| Fluoxetine      | 0.99      | 740207   | $K_i$ (nM)        | mmu      | Norepinephrine transporter                                                     |
| Fluoxetine      | 0.99      | 740208   | $K_i$ (nM)        | mmu      | Dopamine transporter                                                           |
| Imipramine      | 0.99      | 740206   | $K_i$ (nM)        | mmu      | Dopamine transporter                                                           |
| Imipramine      | 0.99      | 740207   | $K_i$ (nM)        | mmu      | Norepinephrine transporter                                                     |
| Imipramine      | 0.99      | 740208   | $K_i$ (nM)        | mmu      | Dopamine transporter                                                           |
| Inuline         | 1.00      | 748943   | $-\log(IC_{50})$ (nM) | rno      | Neuronal acetylcholine receptor protein $\alpha$-7 subunit                     |
| Karacoline      | 1.00      | 748943   | $-\log(IC_{50})$ (nM) | rno      | Neuronal acetylcholine receptor protein $\alpha$-7 subunit                     |
| L-Arginine      | 0.99      | 755144   | Activity (nM)     | hsa      | Nitric-oxide synthase, brain                                                  |
| L-NIL           | 0.59      | 752266   | $-\log(IC_{50})$ (nM) | hsa      | Nitric-oxide synthase, brain                                                  |
| L-NMMA          | 0.99      | 876477   | $-\log(IC_{50})$ (nM) | hsa      | Nitric-oxide synthase, brain                                                  |
| L-NNA           | 0.98      | 752385   | $-\log(IC_{50})$ (nM) | hsa      | Nitric-oxide synthase, brain                                                  |
| L-NNA           | 0.86      | 752276   | $K_i$ (nM)        | hsa      | Nitric-oxide synthase, brain                                                  |
| LY-379268       | 0.99      | 714803   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 4                                             |
| LY-379268       | 0.99      | 877752   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 2                                             |
| LY-379268       | 0.99      | 718128   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 6                                             |
| LY-389795       | 0.99      | 718128   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 6                                             |
| LY-389795       | 0.98      | 715721   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 5                                             |
| LY-389795       | 0.97      | 714446   | Activity (nM)     | hsa      | Metabotropic glutamate receptor 3                                             |
Table 2. Cont.

| Compound (i)          | Assay ID | Measure (Units) | Organism | Target Protein                                                                 |
|-----------------------|----------|-----------------|----------|-------------------------------------------------------------------------------|
|                      | $p_{ij}(c_q)$ |                |          |                                                                               |
| Lycoctonine           | 1.00     | 748943          | −Log(IC$_{50}$) (nM) | rno Neuronal acetylcholine receptor protein α-7 subunit                      |
| M826                 | 1.00     | 841780          | $K_i$ (nM) | hsa Caspase-3                                                                  |
| M827                 | 1.00     | 841780          | $K_i$ (nM) | hsa Caspase-3                                                                  |
| Methyllycaconitine    | 1.00     | 750084          | $K_i$ (nM) | rno Neuronal acetylcholine receptor protein α-10 subunit                      |
| NBQX                  | 0.99     | 641893          | −Log(IC$_{50}$) (nM) | rno Glutamate receptor ionotropic, AMPA 2                                    |
| NBQX                  | 0.99     | 641893          | −Log(IC$_{50}$) (nM) | rno Glutamate receptor ionotropic, AMPA 4                                    |
| NBQX                  | 0.99     | 641893          | −Log(IC$_{50}$) (nM) | rno Glutamate receptor ionotropic, AMPA 3                                    |
| Nipecotic acid        | 0.28     | 785010          | −Log(IC$_{50}$) (nM) | rno GABA transporter 1                                                         |
| Nipecotic acid        | 0.28     | 785010          | −Log(IC$_{50}$) (nM) | rno GABA transporter 2                                                         |
| Nipecotic acid        | 0.28     | 785010          | −Log(IC$_{50}$) (nM) | rno GABA transporter 3                                                         |
| Nipecotic acid        | 0.28     | 785010          | −Log(IC$_{50}$) (nM) | rno Betaine transporter                                                        |
| NOHA                  | 0.04     | 755137          | NO formation (%) | rno Nitric-oxide synthase, brain                                              |
| Norepinephrine        | 0.98     | 780755          | Concentration (% dose·g$^{-1}$) | rno                                                                    |
| Nudicauline           | 1.00     | 748943          | −Log(IC$_{50}$) (nM) | rno Neuronal acetylcholine receptor protein α-7 subunit                      |
| Omega nitro-arginine  | 0.99     | 752258          | $K_i$ (nM) | hsa Nitric-oxide synthase, brain                                              |
| Oxtremorine           | 0.84     | 798083          | pD2       | rno Muscarinic acetylcholine receptor M1                                      |
| Paroxetine           | 1.00     | 740206          | $K_i$ (nM) | mmu Dopamine transporter                                                     |
| RedAm-Ethyl           | 0.33     | 840782          | Selectivity | hsa Nitric-oxide synthase, endothelial                                       |
| RedAm-Ethyl           | 0.28     | 840782          | Selectivity | hsa Nitric-oxide synthase, brain                                              |
| Resveratrol           | 0.99     | 1613870         | EC$_{50}$ (nM) | hsa Nuclear factor NF-κB p105 subunit                                        |
| Resveratrol           | 0.99     | 1613870         | EC$_{50}$ (nM) | hsa Nuclear factor NF-κB p65 subunit                                        |
| Stemofoline           | 1.00     | 936299          | EC$_{50}$ (nM) | hvi Nicotinic acetylcholine receptor α1 subunit                          |
| Thiocytisine          | 0.51     | 857972          | Log $K_i$ | rno Neuronal acetylcholine receptor α4/β2                                    |

$rno$, *Rattus norvegicus* (Rat); mmu, *Mus musculus* (Mouse); hsa, *Homo sapiens* (Human); and hvi, *Heliothis virescens*.

The Table 2 shows predictions of the same drug in different sets of conditions of assay $c_q$, including different targets, organisms, or assays. Therefore, we only have to substitute in the equation the value
of $\theta$s of the compound and the respective values $p^1(c_q)\cdot<\theta^5(s_q)>$ for the MA operators of each condition. In the Table 3 we depict many examples of values of MA operators $p^1(c_q)\cdot<\theta^5(s_q)>$ for different conditions.

2.1.2. Comparison with Other ALMA Models

An interesting exercise is the comparison of the present model and the network predicted with outcomes obtained with other methods. Until the best of our knowledge, there are only two similar models. Both models make use of the spectral moments of a molecular matrix as input variables ($D_i$) to quantify the molecular structure of drugs. The first model [51] applies spectral moments $\mu_k$ of order $k^{th}$ of the bond adjacency matrix ($^1\mathbf{B}$) calculated with the TM approach. The equation of this model is the following:

$$S_0(c_q) = -7.01\times10^{-4}\cdot p(c_j)\cdot \mu_i - 7.8410^{-4}\cdot \Delta \mu_i(s) - 2.93\times10^{-4}\cdot \Delta \mu_i(a) + 1.16\times10^{-4}\cdot \Delta \mu_i(o) + 2.84\times10^{-4}\cdot \Delta \mu_i(t) + 4.198684$$

$$N = 3683\quad R_c = 0.7\quad p < 0.005$$

The second model [52] employs as input the $\pi^k$ values of the Markov matrix ($^1\mathbf{I}$) of atom–atom electron delocalization calculated with the software MI. In the TM method, we weighted the edges of the molecular graph with standard distances of chemical bonds whereas the MI algorithm employs atom standard electronegativities to weighting the nodes of molecular graph. The equation of the second model is:

$$S_0(c_q) = 1.139556 - 0.403994\cdot p(c_j)\cdot \pi_i + 0.199322\cdot \Delta \pi_i(s) + 0.434889\cdot \Delta \pi_i(a) - 0.020189\cdot \Delta \pi_i(o) - 0.001660\cdot \Delta \pi_i(t)$$

$$N = 2661\quad R_c = 0.72\quad \chi^2 = 1913.007\quad p < 0.005$$

In both cases, as well as in the present ALMA-entropy model, we used MA terms to quantify the deviations of the structure of one compound from sub-sets of compounds with a positive outcome in different conditions $c_q$. The three methods showed excellent values of Ac, Sp, and Sn on both training and validation series (see Table 1). Apparently, the TM model shows better values of these parameters but we have to take into consideration the differences in the complexity of the data sets used to train and validate these models. The TM-spectral moment model is able to classify correctly 83%–82% of 4915 cases in total (on training and validation series respectively). The MI-spectral moment model is able to classify correctly 89%–92% of 3598 cases. Notably, the MI-entropy model is able to classify correctly 89%–92% of 8309 cases. Consequently, the statistics for the present model refer to a dataset with more than twice the number of data points present in previous models.
Table 3. Examples of multi-scale, multi-target, or multi-output MA values for different targets, measures, and organisms.

| Experimental Measure (units) | Statistics | Experimental Measure (units) | Statistics | Experimental Measure (units) | Statistics |
|-----------------------------|------------|-----------------------------|------------|-----------------------------|------------|
| n(s)<i><i>1</i></i> | n(s)<i><i>2</i></i> | p(s)<i><i>1</i></i> | 1 | 2 | 3 | 4 | 5 | n(s)<i><i>1</i></i> | n(s)<i><i>2</i></i> | p(s)<i><i>1</i></i> | 1 | 2 | 3 | 4 | 5 | n(s)<i><i>1</i></i> | n(s)<i><i>2</i></i> | p(s)<i><i>1</i></i> | 1 | 2 | 3 | 4 | 5 | n(s)<i><i>1</i></i> | n(s)<i><i>2</i></i> | p(s)<i><i>1</i></i> | 1 | 2 | 3 | 4 | 5 |
| -Log(IC<sub>50</sub>) (nM) | 2438 | 2148 | 0.88 | 2.03 | 2.08 | 2.04 | 2.04 | 2.03 | ED<sub>50</sub> (μg·kg<sup>−1</sup>) | 19 | 14 | 0.74 | 1.58 | 1.6 | 1.59 | 1.59 | 1.59 |
| EC<sub>50</sub> (nM) | 2149 | 1975 | 0.92 | 1.87 | 1.91 | 1.89 | 1.89 | 1.88 | ED<sub>50</sub> (nM) | 18 | 14 | 0.78 | 2.14 | 2.17 | 2.14 | 2.14 | 2.13 |
| K<sub>i</sub> (nM) | 1501 | 1418 | 0.94 | 2.01 | 2.06 | 2.03 | 2.02 | 2.01 | NO formation (%) | 18 | 6 | 0.33 | 0.63 | 0.64 | 0.63 | 0.63 |
| Selectivity | 486 | 102 | 0.21 | 0.5 | 0.51 | 0.51 | 0.51 | 0.51 | Efficiency (%) | 14 | 11 | 0.79 | 1.58 | 1.61 | 1.6 | 1.6 | 1.59 |
| Dopamine release (%) | 299 | 130 | 0.43 | 0.89 | 0.91 | 0.89 | 0.89 | 0.88 | K<sub>up</sub> (mL·min<sup>−1</sup>·g<sup>−1</sup>) | 13 | 5 | 0.38 | 0.75 | 0.76 | 0.76 | 0.76 | 0.76 |
| Activity (%) | 222 | 105 | 0.47 | 1.22 | 1.24 | 1.23 | 1.23 | 1.22 | Conc. (%·dose·g<sup>−1</sup>) | 12 | 7 | 0.58 | 1.14 | 1.15 | 1.14 | 1.14 |
| Inhibition (%) | 193 | 93 | 0.48 | 0.99 | 1 | 0.99 | 0.99 | 0.98 | Efficacy (%) | 12 | 6 | 0.5 | 0.58 | 0.58 | 0.59 | 0.59 |
| Selectivity ratio | 166 | 61 | 0.37 | 0.94 | 0.95 | 0.93 | 0.93 | 0.92 | Ratio K<sub>i</sub> | 12 | 2 | 0.17 | 0.38 | 0.39 | 0.39 | 0.39 |
| Log K<sub>i</sub> | 124 | 72 | 0.58 | 0.96 | 0.97 | 0.96 | 0.96 | 0.96 | MTT reduction (%) | 11 | 4 | 0.36 | 0.58 | 0.57 | 0.56 | 0.56 |
| Ratio | 108 | 31 | 0.29 | 0.66 | 0.67 | 0.66 | 0.66 | 0.65 | Relative potency | 11 | 4 | 0.36 | 0.93 | 0.94 | 0.92 | 0.92 | 0.91 |
| Activity (nM) | 98 | 93 | 0.95 | 1.74 | 1.77 | 1.75 | 1.75 | 1.74 | ED<sub>50</sub> (μg·mL<sup>−1</sup>) | 10 | 4 | 0.4 | 0.99 | 1.02 | 0.99 | 0.99 | 0.98 |
| PCMA antagonism | 84 | 26 | 0.31 | 0.51 | 0.51 | 0.51 | 0.52 | 0.52 | Activity | 8 | 5 | 0.63 | 1.98 | 2.01 | 1.99 | 1.99 | 1.99 |
| -Log(IC<sub>50</sub>) (nM) | 56 | 17 | 0.3 | 0.56 | 0.58 | 0.57 | 0.57 | 0.57 | Damage score | 8 | 2 | 0.25 | 0.5 | 0.51 | 0.5 | 0.49 | 0.49 |
| Ratio (nM) | 56 | 32 | 0.57 | 1.12 | 1.1 | 1 | 1 | 1 | Mean response | 8 | 5 | 0.63 | 1.44 | 1.48 | 1.46 | 1.46 | 1.46 |
| nNOS activity (%) | 36 | 25 | 0.69 | 1.69 | 1.73 | 1.7 | 1.69 | 1.68 | Survived (%) | 8 | 5 | 0.63 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
| %max (%) | 20 | 4 | 0.2 | 0.55 | 0.56 | 0.55 | 0.55 | 0.54 | Rescued neurons (%) | 5 | 2 | 0.4 | 0.59 | 0.6 | 0.61 | 0.62 | 0.63 |
| Organism | n(o<sub>i</sub>) | n<sub>1</sub>(o<sub>i</sub>) | p<sub>1</sub>(o<sub>i</sub>) | 1 | 2 | 3 | 4 | 5 | Organism | n(o<sub>i</sub>) | n<sub>1</sub>(o<sub>i</sub>) | p<sub>1</sub>(o<sub>i</sub>) | 1 | 2 | 3 | 4 | 5 | Organism | n(o<sub>i</sub>) | n<sub>1</sub>(o<sub>i</sub>) | p<sub>1</sub>(o<sub>i</sub>) | 1 | 2 | 3 | 4 | 5 |
| R. norvegicus | 2852 | 1998 | 0.7 | 1.51 | 1.54 | 1.52 | 1.52 | 1.51 | B. taurus | 77 | 21 | 0.27 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| H. sapiens | 4854 | 4090 | 0.84 | 1.82 | 1.86 | 1.83 | 1.82 | C. porcellus | 20 | 16 | 0.8 | 1.35 | 1.36 | 1.35 | 1.35 | 1.35 |
| F. catus | 10 | 7 | 0.7 | 1.66 | 1.7 | 1.68 | 1.67 | 1.66 | H. virescens | 5 | 5 | 1 | 2.78 | 2.83 | 2.78 | 2.78 | 2.76 |
| M. musculus | 241 | 173 | 0.72 | 1.5 | 1.53 | 1.51 | 1.51 | 1.51 | M. domestica | 15 | 15 | 1 | 1.62 | 1.66 | 1.67 | 1.68 | 1.68 |
| T. californica | 19 | 11 | 0.58 | 1.34 | 1.37 | 1.35 | 1.35 | 1.34 | C. elegans | 2 | 1 | 0.5 | 1.28 | 1.31 | 1.28 | 1.27 | 1.26 |
| Gerbillinae | 8 | 2 | 0.25 | 0.5 | 0.51 | 0.5 | 0.49 | 0.49 | D. melanogaster | 2 | 1 | 0.5 | 1.28 | 1.31 | 1.28 | 1.27 | 1.26 |
Table 3. Cont.

| Experimental Measure (units) | Statistics | $p_i(c_i)<\theta_k(c_q)>$ | 1  | 2  | 3  | 4  | 5  |
|-----------------------------|------------|--------------------------|----|----|----|----|----|
| $n(s_i)$ | $n_i(s_i)$ | $p_i(s_i)$ |
| Protein ACC. | $n(t_j)$ | $n_i(t_j)$ | $p_i(t_j)$ | 1.34 | 1.36 | 1.34 | 1.34 | 1.34 | Name |
| Q9UGM1 | 403 | 254 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | Neuronal acetylcholine receptor protein α-9 subunit |
| Q62645 | 77 | 21 | 0.27 | 0.53 | 0.54 | 0.53 | 0.53 | 0.53 | Glutamate (NMDA) receptor subunit ε 4 |
| P35228 | 128 | 32 | 0.25 | 1.30 | 1.32 | 1.30 | 1.30 | 1.30 | Nitric oxide synthase, inducible |
| P29476 | 859 | 562 | 0.65 | 0.50 | 0.51 | 0.50 | 0.50 | 0.50 | NOS, brain |
| P29474 | 88 | 18 | 0.20 | 1.88 | 1.91 | 1.89 | 1.89 | 1.89 | NOS, endothelial |
| P19838 | 1000 | 923 | 0.92 | 1.82 | 1.87 | 1.84 | 1.84 | 1.84 | Nuclear factor NF-κB p105 subunit |
| P12392 | 104 | 90 | 0.87 | 1.78 | 1.83 | 1.80 | 1.80 | 1.79 | Neuronal acetylcholine receptor protein β-4 subunit |
| P12390 | 79 | 66 | 0.84 | 1.97 | 2.04 | 2.01 | 2.01 | 2.00 | Neuronal acetylcholine receptor protein β-2 subunit |
| P12389 | 37 | 31 | 0.84 | 1.98 | 2.02 | 2.00 | 1.99 | 1.98 | Neuronal acetylcholine receptor protein α-2 subunit |
| P09483 | 29 | 28 | 0.97 | 1.82 | 1.87 | 1.84 | 1.84 | 1.82 | Neuronal acetylcholine receptor protein α-4 subunit |
| Assay ID | $n(c_j)$ | $n_i(c_j)$ | $p_i(c_j)$ | 1 | 2 | 3 | 4 | 5 | Details |
| 1613870 | 2000 | 1846 | 0.92 | 1.88 | 1.91 | 1.89 | 1.89 | 1.89 | Expression of NF-κB in human neuronal cells |
| 832611 | 646 | 646 | 1.00 | 2.31 | 2.37 | 2.32 | 2.30 | 2.28 | Inhibition of [3H]EBOB binding to γ-aminobutyric acid GABA–AR |
| 842916 | 390 | 390 | 1.00 | 2.12 | 2.16 | 2.13 | 2.12 | 2.11 | [Ca^{2+}] influx in neonatal rat spinal sensory neuronal culture |
| 792863 | 299 | 130 | 0.43 | 0.89 | 0.91 | 0.89 | 0.89 | 0.88 | Binding of norditerpenoid alkaloids at neuronal α7 nicotinic AChR |
| 899883 | 114 | 99 | 0.87 | 1.46 | 1.48 | 1.46 | 1.46 | 1.45 | Membrane potential in K-177 cells with ACh central neuronal receptor |
| 1041434 | 74 | 17 | 0.22 | 0.56 | 0.57 | 0.56 | 0.56 | 0.56 | mGluR-6 influence in c-AMP formation in rat nonneuronal cells |
| 829510 | 50 | 50 | 1.00 | 2.93 | 2.97 | 2.93 | 2.91 | 2.89 | Inhibition of glutamate induced neuronal death |
| 829508 | 50 | 50 | 1.00 | 2.93 | 2.97 | 2.93 | 2.91 | 2.89 | Inhibition human caspase-1 in neuronal precursor (NT2) cells |
| 829511 | 50 | 50 | 1.00 | 2.93 | 2.97 | 2.93 | 2.91 | 2.89 | Inhibition human caspase-8 in neuronal precursor (NT2) cells |
| 1814959 | 11 | 11 | 1.00 | 2.95 | 3.00 | 2.96 | 2.94 | 2.92 | Blocking permeability of the neuronal Na + in rat striatum slices |
2.1.3. Construction of Drug–Target Networks with ALMA Models

ALMA models may be useful both (1) for computational or virtual High-Throughput Screening (HTS) screening of large databases like CHEMBL and/or (2) for construction of drug–target networks. All the results, discussed in previous section, indicate that many compounds may act as multi-target drugs with non-linear or indirect effect (orthosteric and/or allosteric) over different targets in different pathways. In a recent special issue edited by Csermely, Nussinov, and Szilágyi [60], different research groups discussed about this topic and related concepts such as allo-networks. In one of these papers, Mueller et al. [61] have developed a computational model for the HTS of drugs with action over mGluR5; which represent a promising strategy for the treatment of schizophrenia. Considering the relevance of allotropy for these and other receptors for our study, and all previous comments about allo-network drugs, we decided to use our model to construct a drug-target network. The interest in doing so is that this type of network-based tools may be applied for the discovery of new drugs, including perhaps allo-network drugs [40,60,62].

Considering these points, we constructed here by the first time a drug–target network with CHEMBL experimental outcomes of multiplex assays of neuroprotective effects of drugs with the same dataset used in the previous section. This is probably the first drug–target network representation of the interaction of neuroprotective compounds with cellular or protein targets; many of them susceptible to allosteric modulators. In this directed network, we used three classes of nodes, drugs (\(d_i\)), targets (\(t_j\)), and pharmacological assays (\(a_q\)). They are connected by only three classes of arcs (directed links) drug \(\geq\) (\(d_i \geq t_j\)), drug \(\geq\) assay (\(d_i \geq a_q\)), and target-assay (\(t_j \geq a_q\)). Other types of relationships were not considered. The observed drug–target network was constructed with the input dependent variable \(L_{ij}(c_q)\). In consequence, if CHEMBL reports the case of drug \(d_i\) that causes a strong biological response (\(L_{ij}(c_q) = 1\)) in one biological experiment carry out under the conditions \(c_q = (t_j, a_q)\), we have to draw in the network the path \(d_i \geq t_j \geq a_q\). We omitted here the representation of nodes for the type of experimental measure and the organism that express the target. This avoids very highly connected nodes that may cause a strong distortion in network topology and mask or hidden the relevance of important drugs or targets.

The observed network constructed with the dataset published in the previous work has 968 nodes = 721 drugs + 72 targets + 175 pharmacological assays for neuroprotective effects. We apply, also, the software MI to quantify the structural information of the drug–target networks. In so doing, we calculated the Shannon entropy (Sh), as well as \(\delta = \) node degrees for the nodes (drugs, targets, and assays) in the network, see Table 4. Please note that the Sh entropy values for the nodes in the drug–target network ( supra-molecular structural level) are different from the \(\theta_k\) entropy values use to quantify the information about the structure of the drug (molecular structural level). Actually, we do not use a classic Shannon entropy (H) but a first-order Markov–Shannon entropy [25].

After a first inspection, we can observe that the degree of a node (\(\delta\)) in the network has average values of \(\delta = 4.8 \approx 5\) for all nodes, \(\delta = 4.8 \approx 5\) for drugs, and \(\delta = 4.3 \approx 4\) for assays. It means that, on average, each drug interacts with five targets and we can measure this interaction with approximately four assays. It is easy to realize that the higher \(\delta\) for targets may be determined in part by their position in the network. For each link of drug or assay node, we have two interactions for the target \(d_i \geq t_j\) and \(t_j \geq a_q\). As a result, we can decompose the \(\delta\) into \(\delta = \delta_{in} + \delta_{out} = \) node degree = in-degree + out-degree [63].
For this reason, we carried out all calculations eliminating the direction of arcs. In so doing, we considered them as symmetric links to avoid this “over-booking” of target nodes. Consequently, the average is $\delta = 6.1 \approx 6$ for targets, a value still higher, but closer to 5 than to 8–10, the double is expected.

Table 4. Topological properties of CHEMBL complex networks predicted with ALMA-entropy models.

| Network | Node Type | $n$  | $\text{Sh}_1$* | $\delta$ | $\delta_{\text{in}}$ | $\delta_{\text{out}}$ |
|---------|-----------|-----|----------------|---------|----------------|----------------|
| Total   | Total     | 2450| 0.00428        | 7       | 3               | 3              |
|         | Compounds | 2103| 0.00413        | 6       | 3               | 3              |
| Observed| Assays    | 211 | 0.00575        | 6       | 3               | 3              |
|         | Rat proteins | 54 | 0.00291        | 7       | 4               | 3              |
|         | Human proteins | 70 | 0.00568        | 21      | 18              | 3              |
|         | Total     | 2508| 0.00438        | 7       | 3               | 3              |
|         | Compounds | 2208| 0.00446        | 6       | 3               | 3              |
| 1       | Assays    | 183 | 0.00468        | 15      | 11              | 4              |
|         | Rat proteins | 40 | 0.00279        | 6       | 3               | 3              |
|         | Human proteins | 67 | 0.00210        | 5       | 1               | 3              |
|         | Total     | 2511| 0.00428        | 7       | 3               | 3              |
|         | Compounds | 2209| 0.00445        | 6       | 3               | 3              |
| 2       | Assays    | 184 | 0.00464        | 15      | 11              | 4              |
|         | Rat proteins | 40 | 0.00266        | 6       | 3               | 3              |
|         | Human proteins | 68 | 0.00209        | 4       | 1               | 3              |
|         | Total     | 2511| 0.00444        | 7       | 3               | 3              |
|         | Compounds | 2209| 0.00445        | 6       | 3               | 3              |
| 3       | Assays    | 184 | 0.00464        | 15      | 11              | 4              |
|         | Rat proteins | 40 | 0.00266        | 6       | 3               | 3              |
|         | Human proteins | 68 | 0.00209        | 4       | 1               | 3              |
|         | Total     | 2491| 0.0046        | 7       | 3               | 3              |
|         | Compounds | 2209| 0.00471        | 6       | 3               | 3              |
| 4       | Assays    | 184 | 0.00449        | 14      | 11              | 4              |
|         | Rat proteins | 40 | 0.00251        | 6       | 2               | 3              |
|         | Human proteins | 68 | 0.00209        | 4       | 1               | 3              |
|         | Total     | 2491| 0.0046        | 7       | 3               | 3              |
|         | Compounds | 2209| 0.00471        | 6       | 3               | 3              |
| 5       | Assays    | 184 | 0.00449        | 14      | 11              | 4              |
|         | Rat proteins | 40 | 0.00251        | 6       | 2               | 3              |
|         | Human proteins | 68 | 0.00209        | 4       | 1               | 3              |

*a $\delta = \delta_{\text{in}} + \delta_{\text{out}}$ = node degree = in-degree + out-degree, $\text{Sh}_1$ = Shannon entropy of Markov chain (measure of information).

In a second stage, we use our model to reconstructing/predicting the same network, based on the probability $p(m_j)$ outputs of the model. Two nodes are connected when the probability predicted by the model is $p(c_q) > 0.5$, it means that $p(d_i, t_j)$, or $p(d_i, a_q)$, or $p(t_j, a_q)$ are >0.5, for different pairs of links. We can perceive that the values of the drug–target network predicted by the model are very similar to
those of the observed network. Consequently, we can conclude that the model is efficient not only in the overall prediction of links in the network (high Ac, Sp, and Sn, see Table 1) but in the reconstruction of topological patterns. For instance, from information theory we can deduce that the uncertainty of links is similar in both networks because Shannon entropy calculated for all links is $S_{\text{obs}} = 0.005 - 0.007 \approx S_{\text{pred}} = 0.004 - 0.006$. In Figure 1, we represented the Observed (A) vs. Predicted (B) complex networks.

Figure 1. Multitarget, Multiscale, and Multi-output networks, of CHEMBL sub-set of neuroprotection related drugs (yellow), targets (red), and pharmacological assays (green) Observed (A) vs. Predicted (B).

2.2. Experimental and Theoretical Study of New Compounds

2.2.1. Synthesis and Experimental Assay of New 1,2-Rasagiline Derivatives

The compounds 2, 3, 4, 5, 6, 7, 8, and 9 were synthesized according to the strategy given in Figure 2. As shown in this scheme, they were synthesized from the aminoalcohol 1 [(1R,2S)-(+)1-amino-2-
indanol], a commercial product. The alkylation of 1 with propargyl bromide and potassium carbonate in hot acetonitrile provided, in a global yield of 92%, a mixture of the corresponding mono- and dipropargylated derivatives (2 and 3), which were separated by flash column chromatography using hexane/EtOAc (3:1) as eluent. Compound 3 was converted to the corresponding acetate (4) and benzoate (5) by treatment with acetic anhydride or benzoyl chloride, Et3N and catalytic amounts of 4-dimethylaminopyridine (DMAP) in MeCN. The carbamate derivatives (6, 7, 8, and 9) were synthesized, from the hidroxy mono- or dipropargylaminoindans (2 and 3), by reaction with the corresponding dialkylcarbamyl chloride in NaH and acetonitrile following the procedure described in the literature [64].

Figure 2. Synthesis of compounds 2–9.

The new compounds synthesized in this work (2, 3, 4, 5, 6, 7, 8, and 9) were subjected to an initial study to determinate its neuroprotective ability in both the presence and the absence of neurotoxic agents (ANA). The method of reduction of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used to ascertain the cell viability, given by the number of cells present in the culture. The ability of cells to reduce MTT is an indicator of the integrity of mitochondria, and its functional activity is interpreted as a measure of cell viability [65]. Three assays were conducted in a culture of motor cortex neurons of 19-day-old Sprague–Dawley rat embryos. All results are expressed as the mean ± S.E.M. [51,52] of at least three independent experiments (Table 5).
Firstly, we studied the ability to induce a neuroprotective effect in the absence of any neurotoxic stimulation. Secondly, we studied the neuroprotective effect in the presence of glutamate, a compound that causes a pathological process, in which neurons are damaged leading to apoptosis when its receptors, such as the NMDA and AMPA, are over-activated. Lastly, the ability of the compounds synthesized to protect from damage by H_{2}O_{2}, that causes neuronal death by oxidative stress, was analyzed. The results obtained allow to deduce the existence of a moderate neuroprotective effect in the absence of any toxic stimulus, presenting the best results type 6 and 9 carbamate derivatives, with values of 11.5% and 8.4%, respectively, followed by the compound 3, 4, and 7 with values slightly above 4% (see Figure 3).

### Table 5. Neuroprotective ability of the new 1,2-rasagiline derivatives.

| Compound | Formula | % ANA \(^a\) | e.s.m. | Glutamate \(^b\) | e.s.m. | H_{2}O_{2} \(^c\) | e.s.m. |
|----------|---------|---------------|--------|----------------|--------|----------------|--------|
| 2 | ![2](image) | 0.0 | 2.8 | 0.0 | 6.5 | −2.8 | 1.2 |
| 3 | ![3](image) | 4.7 | 6.0 | −0.2 | 1.6 | −12.3 | 2.1 |
| 4 | ![4](image) | 4.2 | 6.5 | −8.1 | 4.9 | −14.2 | 2.1 |
| 5 | ![5](image) | 1.2 | 5.0 | 3.8 | 5.0 | 2.9 | 1.0 |
| 6 | ![6](image) | 11.5 | 8.8 | −4.0 | 5.5 | −9.1 | 2.4 |
| 7 | ![7](image) | 4.0 | 4.5 | 2.6 | 3.9 | −6.1 | 1.1 |
| 8 | ![8](image) | −1.7 | 6.9 | −5.2 | 5.9 | −8.9 | 1.9 |
| 9 | ![9](image) | 8.4 | 10.7 | −5.2 | 2.3 | −14.0 | 2.0 |

\(^a\) % protection (comp 5 µM), in the Absence of Neurotoxic Agents (ANA); \(^b\) % protection (comp 5 µM) against Glutamate 100 µM; \(^c\) % protection (comp 5 µM) against H_{2}O_{2} 100 µM.
2.2.2. Using ALMA-Entropy Model to Predicting New Drugs in Other Assays

We used the ALMA-entropy model to predicting the more probable results for all the new rasagiline derivatives synthesized in this work, in >500 assays not carried out experimentally. When the molecular descriptors (entropy indices) of the new rasagiline derivatives were introduced in our model, we obtained the probable interaction with different targets. The model predicts that most of them could interact with the subunits A and B of the 5-hidroxy-tryptamine type 3 receptors (5-HT3Rs), see Table 6. These results seem to be consistent with the literature, since the antagonists of 5-HT3Rs have been related to neuroprotective properties \textit{in vitro} and \textit{in vivo} \cite{66}. In fact, this could be a potential mechanism of neuroprotection added to several described mechanisms for rasagiline derivatives \cite{67,68}. Rasagiline is also known for promoting serotonergic activity by other ways, which is a clinically relevant fact in certain circumstances \cite{69}. All in one highlights the intricate relationships of these drugs with the 5-hidroxy-tryptamine (serotonine) system.

Table 6. Some predictive results for interaction between compound 6 with 5HT3Rs and other targets.

| $S(c_j)$ | Measure   | Assay ID | Target ID | Target | Neurotoxic Agent |
|----------|-----------|----------|-----------|--------|-----------------|
| 2.097    | pA2       | 617971   | 1899      | 5HT3aR | ANA             |
| 2.097    | pA2       | 617969   | 1899      | 5HT3aR | ANA             |
| 2.097    | pA2       | 617971   | 3895      | 5HT3bR | ANA             |
| 2.097    | pA2       | 617969   | 3895      | 5HT3bR | ANA             |
| 1.78     | Selectivity | 848737  | 3568      | bNOS   | H$_2$O$_2$      |
| 1.78     | Selectivity | 840777  | 3568      | bNOS   | H$_2$O$_2$      |
| 1.78     | Selectivity | 755901  | 3568      | bNOS   | H$_2$O$_2$      |
| 1.17     | Activity (%) | 866501  | 2586      | nAChRβ-3 | H$_2$O$_2$  |
| 0.42     | pIC$_{50}$ (nM) | 710048  | 3772      | mGluR1 | Glu             |

$^a$ nAChRβ-3 = neuronal acetyl-choline receptor β3, mGluR1 = metabotropic glutamate receptor type 1.
In any case, we need to analyze these results with caution. In our previous works [51,52], we predicted with new models and confirmed experimentally that some rasagiline derivatives (similar to the derivatives studied in this work) presented activity over glutamate receptors (GluRs) pathway. In the first of these works [51], we study experimental measures of neuroprotective capacity of new 1,3-rasagiline derivatives. All the compounds, except one of them, had a high protective activity against damage mediated by H2O2. The best one of all, a monopropargyl trans derivative, showed also a high neuroprotective action in all three type of assays. Our first model predicted for this compound high probability of activity in relationship with acetylcholine and GABA, in addition to GluRs. In coincidence, acetylcholine receptors (AChRs) have been associated with neuroprotective proprieties in several recent experimental works, and there are also reports of association of GABA and GluRs with neuroprotective ability [70,71]. Nuritova et al. [72], discussed a neuroprotective strategy involving retrograde release of glutamate.

In our second work [52], we studied two types of substituent groups (propargyl groups attached to the nitrogen and a carbamate or ester group instead of hydroxyl). The compounds also presented two different chirality patterns but with 1,3 substitutions pattern. The compounds of this second series were active experimentally in the absence and presence of neurotoxic agents. The best compound of this second series, a dipropargyl derivative, was predicted to have brain nitric oxide synthase (bNOS) as the most probable target and certain probability of multi-target ligand. Again, bNOS was associated experimentally with neuroprotective action in several works [73,74].

The compounds studied this third work present similar substituent groups and stereochemistry but one 1,2 substitution pattern. Based on the previous results, we should expect a similar experimental activity and predictions. However, in the previous section we shown experimentally that the present set of compounds seems not to be very active over GluRs and the model predicts the higher scores of activity over 5-HT3Rs instead of the expected receptors. As we stated in the previous paragraph, 5-HT3Rs have been related to neuroprotective properties in vitro and in vivo [66]. A plausible hypothesis (pendent of further experimental confirmation) is the variation in receptor affinity (from GluRs to 5-HT3Rs pathway) due to the change from 1,3 to 1,2 substitution pattern. From our point of view, these correspondences between targets that our equations predict, and the references cited from the literature could indicate biological plausibility of our models.

3. Materials and Methods

3.1. Computational Methods

3.1.1. ALMA-Entropy Models

ALMA models may be classified as a general type of model to assessing the links in different systems. They are adaptable to all molecular descriptors and/or graphs invariants or descriptors for complex networks. In general, we refer to a descriptor $D_{ik}$ of type $k^{th}$ of the $i^{th}$ system (compound or drug $d_i$ in this case) represented by a matrix $M$. In fact, in this work we are going to compare the model based on entropy values $\theta_{ik}$ of a Markov matrix $^1\Pi$ with other ALMA models based on other invariants of the same matrix $^1\Pi$, or invariants of the bond adjacency matrix $^1B$. Consequently, we describe first the general equations of the model using a generic descriptor, or graph theoretical
invariant $D^k$, and later we give the specific equation for the entropy model based on $\theta^k$ values. The aim of this model is to link the scores $S_{ij}(c_q)$ with the molecular descriptors $D^k$ of a given compound $d_i$ and the Box–Jenkins MA operators written in the form of deviation terms $\Delta D^k(c_q) = D^k - <D^k(c_q)>$. The model has the following general form:

$$S_{ij}(c_q) = a_0 + \sum_{k=0}^{k=5} a_k \cdot S^k + \sum_{q=1}^{q=5} \sum_{k=0}^{k=5} a_{jk} \cdot S^k$$

$$= a_0 + \sum_{k=0}^{k=5} a_k \cdot p(c_l) \cdot D^k + \sum_{q=1}^{q=5} \sum_{k=0}^{k=5} a_{jk} \cdot \Delta D^k$$

(5)

The output dependent variable is $S_{ij}(c_q) = S_{ij}(c_1, c_2, c_3, c_4, c_5) = S_{ij}(c_1, a_q, o_t, t_j, s_x)$. The variable $S_{ij}(c_q)$ is a numerical score of the biological activity of the $i$th drug ($d_i$) vs. the $j$th target measured in one assay carried out under the set of $c_q$ conditions. Our hypothesis is $H_0$: we can calculate the output $S_{ij}(c_q)$ as a linear combination of scores. We have two types of scores. The first type are the scores $S^k = a_k \cdot p(c_l) \cdot D^k$ that account for the quality of data $p(c_l)$ and for contributions of the $k$th molecular descriptors to the final activity score $S_{ij}(c_q)$. In fact, we used the probability $p(c_1) = 1.0; 0.75; 0.5$ for data curated in CHEMBL database at levels of expert, intermediate, or auto-curation level, respectively. The second type are scores $D^k = a_k \cdot \Delta D^k(c_q)$ for the contributions of deviations $\Delta D^k(c_q) = (D^k - <D^k(c_q)>)$ of the descriptors of $d_i$ from the average of those of active molecules $L_{ij}(c_q) = 1$ for different $c_q$. In general, $c_j$ refers to different Multi-output assay conditions, e.g., targets, assays, cellular lines, organisms, organs, etc. In this sense, $c_0$ is the accuracy of the data for this assay, $c_1 = a_0$ is the assay per se, $c_2 = a_1$ is the organism that expresses the target, $c_3 = t_j$ is the $j$th cellular or molecular target, and $c_5 = s_x$ is standard experimental measure of activity. Then, the parameter $D^k$ and $\Delta D^k(c_q)$ are the input independent variables and $L_{ij}(c_q) = 1$ is the input dependent variable. Here, $<D^k(c_q)>$ is the average of the $k$th descriptors $D^k$ of all $i$ compounds considered as active ($L_{ij}(c_q) = 1$) in an assay carry out under the set of conditions $c_q$. The parameters $\Delta D^k(c_q)$ are similar to the MA used in time series analysis for Bob–Jenkins ARIMA models and others [42]. This type of MA model has been used before to solve different problems in Cheminformatics before. It means that, firstly, we sum the values of $D^k$ for all the $n_j$ drugs with $L_{ij}(c_q) = 1$ in the assay carry out in the conditions $c_j$. Next, we divide this sum by the number of compounds $n_j$ with this condition.

$$\langle D^k \rangle = \frac{1}{n_q} \sum_{i=1}^{i=n_j} D^k$$

(6)
In this model, we used only one molecular descriptor \( \theta^5 \). This is the Shannon entropy of order \( k = 5 \) calculated with MI. We do not use low-order entropies \( k = 0, 1, 2, 3, \) and \( 4 \). Accordingly, the general equation is:

\[
S_0(c_q) = a_0 + a_1 S^1(c_q) + \sum_{q=1}^{5} a_{q} S^q(c_q) \\
= a_0 + a_1 \cdot p(c_q) \cdot \theta^1 + \sum_{q=1}^{5} a_{q} \cdot \Delta \theta^q(c_q) \tag{7}
\]

This type of moving average or deviation-like models was coined by us as the ALMA models, and has been used before to solve different problems [54,75–77]. In order to seek the model we used the technique Linear Discriminant Analysis (LDA) implemented in the software package STASTICA 6.0 [78]. The statistical parameters used to corroborate the model were: Number of cases in training (\( N \)), and overall values of Sp, Sn, and Ac [54].

3.1.2. CHEMBL Dataset

We downloaded from the public database CHEMBL a general data set composed of >8000 Multi-output assay endpoints (results of multiple assays) [33,34]. We assigned a value of the observed (obs) class variable \( L_{ij}(c_q)_{obs} = 1 \) (active compound) or \( L_{ij}(c_q)_{obs} = 0 \) (non-active compounds) to every \( i \)th drug biologically assayed in different conditions \( c_j \). The dataset used to train and validate the model includes \( N = 3548 \) statistical cases, formed by \( N_i = 3091 \) unique drugs which have been assayed each one in at least one out of 37 possible standard type measures determined in, at least, one out of 493 assays. Each assay involves, in turn, at least one out of 169 molecular or cellular targets expressed in the tissues of at least one out of 11 different organisms (including human).

3.2. Experimental Methods: Chemistry

3.2.1. Synthesis of 1,2-Rasagiline Derivatives

Melting points are uncorrected and were determined in Reichert Kofler Thermopan (Reichert, Vienna, Austria) or in capillary tubes on a Büchi 510 apparatus (BÜCHI Labortechnik AG, Flawil, Switzerland). Infrared spectra were recorded on a JASCO FT/IR-4100 spectrophotometer (JASCO Analytical Instruments, Easton, PA, USA). The \(^1\)H-NMR spectra (300 MHz) and \(^{13}\)C-NMR spectra (75 MHz) were recorded in a Bruker AMX spectrometer (Bruker BioSpin Corporation, Fremont, CA, USA), using TMS as internal reference (chemical shifts in \( \delta \) values, \( J \) in Hz). EI Mass spectra were recorded on a HEWLETT-PACKARD 5988A spectrometer (Hewlett-Packard Company, Palo Alto, CA, USA). FABMS were obtained using MICROMASS AUTOSPEC mass spectrometer (WATERS, Milford, MA, USA) and ESI-MS were determined on a BRUKER AMAZON ETD spectrometer (Bruker BioSpin Corporation). We performed microanalyses in a Perkin-Elmer 240B elemental analyzer (PerkinElmer, Waltham, MA, USA) by the Microanalysis Service of the University of Santiago de Compostela. The specific rotation was measured with a PERKIN-ELMER 241 polarimeter.
(PerkinElmer), and it is expressed in (°) (dm−1) (g−1) (mL). Most of the reactions were monitored by TLC on pre-coated silica gel plates (Merck 60 F254, 0.25 mm, Merck KGaA, Darmstadt, Germany). Synthesized products were purified by flash column chromatography on silica gel (Merck 60, 230–240 mesh, Merck KGaA) and crystallized if necessary. Solvents were dried by distillation prior use.

Compound (3): (1S,2R)-(+)-cis-1-(N-Propargylamino)-2-indanol (2) and (1S,2R)-(+)-cis-1-(N,N-dipropargylamino)-2-indanol. A mixture of 1 (0.20 g, 1.34 mmol), K2CO3 (0.18 g, 1.34 mmol) and MeCN (7 mL) was stirred at room temperature under argon for 5 min. A solution of propargyl bromide (0.3 mL, 2.7 mmol) dissolved in MeCN (2 mL) was added dropwise with stirring. After being stirred for 24 h, the solvent was evaporated and the residue was dissolved in EtOAc (10 mL). The organic layer was washed with NaOH 2N (3 × 10 mL) and dried (Na2SO4). The removal of excess of solvent to give a white solid, that was purified by flash column chromatography using hexane/EtOAc (3:1) as eluent to give, in first place 3 (170 mg, yield 56%) as a white solid and in second place 2 (90 mg, yield 36%) as a white solid.

(+)-cis-2. M.p. 106–108 °C. [α]D25° = +38° (25 °C, 0.25, CHCl3). IR ν = 3277, 2906, 1421, 1339, 1140, 1051, 731 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.32–7.22 (m, 4H, H arom), 4.51–4.47 (m, 1H, 2-H), 4.31–4.29 (m, 1H, 1-H), 3.69–3.52 (AB system, 1H, J = 17.2 Hz, CH2), 3.68–3.51 (AB system, 1H, J = 17.2 Hz, CH2), 3.11–2.96 (m, 2H, 3α-H, 3β-H), 2.67 (br. s., 1H, D2O exch., OH), 2.31 (t, 1H, J = 2.2 Hz, CH). 13C RMN (75 MHz, CDCl3) δ = 141.85 (C-3a), 141.05 (C-7a), 128.17, 126.79, 125.58 and 123.94 (CH arom), 82.27 (C-CH), 71.90 (C-2), 70.87 (C=CH), 64.78 (C-1), 39.59 (CH2), 37.16 (C-3). MS (EI): m/z (%): 186 (2) [M–H2O]+, 185 (100) [M+], 170 (2) [M–propargyl]–, 148 (100) [M–propargyl]−, 130 (21), 115 (10), 103 (31), 77 (11). Anal. calcd. for C12H13NO (187.24): C 76.98, H 7.00, N 7.48; found C 76.63, H 7.12, N 7.36.

(+)-cis-3. M.p. 106–109 °C. [α]D25° = +72° (25 °C, 0.25, CHCl3). IR ν = 3279, 2894, 1339, 1244, 1137 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.52–7.50 (m, 1H, 7-H), 7.29–7.18 (m, 3H, 4-H, 5-H, 6-H), 4.52 (dd, 1H, J = 13.2, 6.9 Hz, 2-H), 4.42–4.40 (m, 1H, 1-H), 3.74 (br. s., 1H, D2O exch., OH), 3.65–3.39 (AB system, 2H, J = 17.1 Hz, CH2), 3.64–3.38 (AB system, 2H, J = 17.1 Hz, CH2), 3.24–2.79 (part AB of an ABM system, 2H, JAB = 16.4 Hz, JAM = 7.2 Hz, JBM = 6.1 Hz, 3α-H, 3β-H), 2.29 (t, 2H, J = 2.3 Hz, 2 × CH). 13C RMN (75 MHz, CDCl3) δ = 141.47 (C-3a), 138.15 (C-7a), 128.68, 127.04, 126.65 and 125.46 (CH arom), 80.37 (2 × C=CH), 72.87 (C-2), 71.39 (2 × C=CH), 68.37 (C-1), 41.04 (2 × CH2), 40.31 (C-3). MS (EI): m/z (%): 226 (2) [M+1]+, 225 (5) [M]+, 224 (4) [M–1]+, 208 (2) [M–H2O]–, 186 (100) [(M–1)–propargyl]. Anal. calcd. for C15H15NO (225.29): C 79.97, H 6.71, N 6.22; found C 79.81, H 6.92, N 6.29.

Compound (4): (1S,2R)-(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl acetate. A mixture of 3 (0.08 g, 0.36 mmol), acetic anhydride (66 µL, 0.72 mmol), Et3N (100 µL, 0.72 mmol), DMAP (a catalytic amount) in MeCN (5 mL), under argon, was stirred at room temperature for 3 h. The solvent was removed and the residue was partitioned between EtOAc (10 mL) and H2O (10 mL), and the organic layer was washed with a saturated solution of NaCl (3 × 10 mL), dried (Na2SO4) and evaporated, to give 4 (as a white solid (76 mg, yield 80%)). M.p. 52–53 °C. [α]D25° = −70.6° (25 °C, 0.25, CHCl3). IR ν = 3239, 2890, 1729, 1210, 1035 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.49–7.46 (m, 1H, 7-H), 7.31–7.21 (m, 3H, 4-H, 5-H, 6-H), 5.68 (dt, 1H, J = 5.4, 2.4 Hz, 2-H), 4.61 (d, 1H, J = 5.4 Hz, 1-H), 3.77–3.63 (AB system, 2H, J = 17.5 Hz, CH2), 3.76–3.62 (AB system, 2H, J = 17.3 Hz, CH2),
3.17–2.93 (part AB of an ABM system, 2H, $J_{AB} = 17.2$ Hz, $J_{AM} = 5.7$ Hz, $J_{BM} = 2.5$ Hz, 3α-H, 3β-H), 2.21 (t, 2H, $J = 2.4$ Hz, 2 × CH), 2.02 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) $\delta = 170.40$ (COCH3), 140.01 (C-3a), 139.48 (C-7a), 128.07, 126.97, 125.24 and 125.13 (CHarom), 81.21 (2 × C≡CH), 77.04 (C-2), 68.94 (2 × CH2), 39.99 (2 × CH2), 37.68 (C-3), 21.70 (CH3). MS (FAB): $m/z$ (%): 269 (6) [M+2]+, 268 (26) [M+1]+, 225 (2) [M–acetyl], 197 (18), 169 (12), 154 (88), 137 (100). Anal. calcd. for C17H17NO2 (267.32): C 76.38, H 6.41, N 5.24; found C 76.12, H 6.68, N 5.36.

Compound (5): (1S,2R)−(−)−cis-1-(N,N-Dipropargylamino)-2-indanyl benzoate. To a solution of 3 (0.08 g, 0.36 mmol), DMAP (a catalytic amount) in MeCN (5 mL), at 0 °C and under argon, was added dropwise a solution of benzoyl chloride (82 μL, 0.72 mmol) and Et3N (100 μL, 0.72 mmol). The mixture was stirred at room temperature for 2 h. the solvent was evaporated and the residue was dissolved in CH2Cl2 (10 mL). The layer organic was washed with a saturated solution of NaCl (3 × 10 mL), dried (Na2SO4) and evaporated, to give a yellow oil that was purified by flash column chromatography using hexane–EtOAc (6:1) as eluent to give 5 (73 mg, yield 73%) as a yellow oil. $[\alpha]_{D}^{25^\circ} = −85.6^\circ$ (25 °C, 0.25, CHCl3). IR $\nu = 3289, 2842, 1714, 1267, 1108, 1069$ cm$^{-1}$. 1H NMR (300 MHz, CDCl3) $\delta = 7.95–7.92$ (m, 2H, 2'-H, 6'-H), 7.56–7.50 (m, 7H, 3'-H, 4'-H, 5'-H, 4 × H arom), 6.00 (dt, 1H, $J = 5.6, 2.6$ Hz, 2-H), 4.74 (d, 1H, $J = 5.3$ Hz, 1-H), 3.75 (d, 4H, $J = 2.3$ Hz, 2 × CH2), 3.29–3.06 (part AB of an ABM system, 2H, $J_{AB} = 17.0$ Hz, $J_{AM} = 5.7$ Hz, $J_{BM} = 2.7$ Hz, 3α-H, 3β-H), 2.15 (t, 2H, $J = 2.1$ Hz, 2 × CH). 13C NMR (75 MHz, CDCl3) $\delta = 166.36$ (CO), 140.30 (C-3a), 139.81 (C-7a), 133.16 (C'-4), 129.83, 128.61, 128.39, 127.28, 125.49 and 125.43 (4 × CH arom, 4 × C'-H), 81.30 (2 × C≡CH), 77.75 (C-2), 72.20 (2 × C≡CH), 69.17 (C-1), 40.40 (2 × CH2), 38.13 (C). MS (FAB): $m/z$ (%): 331 (11) [M+2]+, 330 (40) [M+1]+, 231 (68), 186 (3), 154 (95), 137 (100), 105 (25). Anal. calcd. for C22H19NO2 (329.39): C 80.22, H 5.81, N 4.25; found C 80.05, H 6.01, N 4.34.

3.2.2. Reaction of Carbamylation

To a stirred and ice-cooled solution of 2 or 3 (0.43 mmol) in acetonitrile (5 mL) was added the N,N-dialkylcarbamyl chloride (0.73 mmol), followed by a dropwise addition of NaH (60% in oil, 0.56 mmol). The reaction mixture was stirred for 24 h at room temperature under argon. After evaporation of the solvent in vacuo, water (10 mL) was added and extracted with ether (3 × 10 mL). The organic phase was washed with dilute KOH (pH 10–11), dried and evaporated to dryness in vacuo. Purification by column chromatography (Hexane:EtOAc 6:1) afforded:

Compound (6): (1S,2R)−(−)−cis-1-(N-Propargylamino)-2-indanyl dimethylcarbamate. This compound was obtained as a yellow solid (100 mg, yield 73%). M.p. 119–122 °C. $[\alpha]_{D}^{50^\circ} = −50.4^\circ$ (23 °C, 0.25, CHCl3). IR $\nu = 3264, 2923, 1693, 1388, 1184, 1047$ cm$^{-1}$. 1H NMR (300 MHz, CDCl3) $\delta = 7.40–7.39$ (m, 1H, 7-H), 7.28–7.13 (m, 3H, 4-H, 5-H, 6-H), 5.52–5.48 (m, 1H, J = 5.0 Hz, 1-H), 3.61–3.46 (AB system, 1H, $J = 16.8$ Hz, CH2), 3.60–3.45 (AB system, 1H, $J = 16.8$ Hz, CH2), 3.19–3.04 (AB system, 1H, $J = 16.5$ Hz, 3α-H), 3.17–3.03 (AB system, 1H, $J = 16.5$ Hz, 3β-H), 2.90–2.80 (m, 6H, 2 × CH3), 2.62 (t, 1H, $J = 2.5$ Hz, CH), 2.25 (br. s., 1H, D2O exch., NH). 13C NMR (75 MHz, CDCl3) $\delta = 155.97$ (CO), 142.09 (C-3a), 139.75 (C-7a), 127.97, 126.69, 124.93 and 124.66 (CHarom), 82.17 (C≡CH), 76.00 (C-2), 71.64 (C≡CH), 63.28 (C-1), 37.46 (CH2), 36.35 (C-3), 29.94
and 29.67 (2 × CH₃). MS (FAB): m/z (%): 258 (1) [M⁺], 257 (6) [M−1⁺], 168 (100), 116 (80), 72 (80). Anal. calcd. for C₁₅H₁₈N₂O₂ (258.32): C 69.74, H 7.02, N 10.84; found C 69.65, H 7.13, N 10.93.

Compound (7): (1S,2R)−(−)-cis-1-(N-Propargylamino)-2-indanyl diethylcarbamate. Isa yellow solid (98 mg, yield 66%). M.p. 68−69 °C. [α]D²⁵ = −37.6° (23 °C, 0.25, CHCl₃). IR ν = 3242, 2972, 1677, 1425, 1173, 1066 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ = 7.42−7.39 (m, 1H, 7-H), 7.29–7.21 (m, 3H, 4-H, 5-H, 6-H), 5.54 (dt, 1H, J = 5.3, 3.6 Hz, 2-H), 4.41–4.39 (m, 1H, 1-H), 3.63–3.49 (AB system, 1H, J = 16.8 Hz, CH₂), 3.29–3.09 (m, 6H, 3α-H, 3β-H, 2 × CH₂CH₃), 2.25 (t, 1H, J = 2.4 Hz, CH), 1.93 (br. s., 1H, D₂O exch., NH), 1.28–1.01 (m, 6H, 2 × CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃) δ = 155.18 (CO), 139.80 (C-7a), 127.91, 126.65, 124.88 and 124.61 (CH arom), 82.19 (C≡CH), 75.64 (C-2), 63.52 (C-1), 41.92 and 41.30 (2 × CH₂CH₃). MS (FAB): m/z (%): 288 (18) [M+2]⁺, 287 (100) [M+1]⁺, 286 (8) [M−1]⁺, 231 (21), 154 (27), 137 (26). Anal. calcd. for C₁₇H₂₂N₂O₂ (286.37): C 71.30, H 7.74, N 9.78; found 71.12, H 7.99, N 9.92.

Compound (8): (1S,2R)−(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl dimethylcarbamate. Was obtained as a white solid (76 mg, yield 58%). M.p. 109–112 °C. [α]D²⁵ = −38° (25 °C, 0.25, CHCl₃). IR ν = 3292, 2922, 1685, 1397, 1272, 1186, 1050 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ = 7.48 (t, 1H, J = 3.9 Hz, 7-H), 7.27−7.22 (m, 3H, 4-H, 5-H, 6-H), 5.61 (dt, 1H, J = 5.6, 3.3 Hz, 2-H), 4.63–4.61 (m, 1H, 1-H), 3.67–3.66 (m, 4H, 2 × CH₂), 3.16–2.97 (AB system, 1H, J = 16.8 Hz, 3α-H), 3.14–2.96 (AB system, 1H, J = 16.8 Hz, 3β-H), 2.91–2.81 (m, 6H, 2 × CH₃), 2.21 (t, 1H, J = 2.2 Hz, 2 × CH) ¹³C NMR (75 MHz, CDCl₃) δ = 155.98 (CO), 139.98 (C-3a), 139.86 (C-7a), 127.96, 126.76, 125.39 and 125.10 (CH arom), 81.10 (2 × C≡CH), 77.36 (C-2), 71.91 (2 × C≡CH), 68.31 (C-1), 40.24 (2 × CH₂), 37.94 (C-3), 36.49 and 36.14 (2 × CH₃). MS (FAB): m/z (%): 298 (18) [M+2]⁺, 297 (100) [M+1]⁺, 286 (8) [M]⁺, 285 (6) [M−1]⁺, 231 (21), 154 (27), 137 (26). Anal. calcd. for C₁₇H₂₂N₂O₂ (286.37): C 71.30, H 7.74, N 9.78; found 71.12, H 7.99, N 9.92.

Compound (9): (1S,2R)−(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl diethylcarbamate. This compound was obtained as an oil (70 mg, yield 49%). [α]D²⁵ = −18.6° (25 °C, 0.25, CHCl₃). IR ν = 3292, 2928, 1688, 1425, 1270, 1167, 1062 cm⁻¹. ¹H NMR (300 MHz, CDCl₃) δ = 7.49 (t, 1H, J = 4.2 Hz, 7-H), 7.28–7.23 (m, 3H, 4-H, 5-H, 6-H), 5.59 (dt, 1H, J = 5.8, 3.9 Hz, 2-H), 4.62 (d, 1H, J = 5.8 Hz, 1-H), 3.71–3.57 (m, 4H, 2 × CH₂), 3.35–3.23 (m, 4H, 2 × CH₂CH₃), 3.17–2.98 (AB system, 1H, J = 16.8 Hz, 3α-H), 3.15–2.97 (AB system, 1H, J = 16.8 Hz, 3β-H), 2.21 (t, 2H, J = 2.2 Hz, 2 × CH), 1.12–1.01 (m, 6H, 2 × CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃) δ = 155.21 (CO), 139.98 (C-3a), 139.86 (C-7a), 128.00, 126.74, 125.55 and 125.01 (CH arom), 81.06 (2 × C≡CH), 76.58 (C-2), 71.97 (2 × C≡CH), 67.99 (C-1), 41.65 and 41.12 (2 × CH₂CH₃), 40.14 (2 × CH₂), 37.81 (C-3), 13.97 and 13.47 (2 × CH₂CH₃). MS (FAB): m/z (%): 326 (20) [M+2]⁺, 325 (92) [M+1]⁺, 324 (2) [M]⁺, 323 (8) [M−1]⁺, 288 (89), 230 (51), 154 (71), 137 (100). Anal. calcd. for C₂₀H₂₄N₂O₂ (324.42): C 74.04, H 7.46, N 8.64; found 73.89, H 7.61, N 8.75.
3.3. Experimental Methods: Biology

3.3.1. Culture of Rat Cortical Neurons

Embryos were selected from 19 to 20 days pregnant rats by caesarean section. Meninges were removed and cortex was isolated after the dissection of the brain. The fragments obtained from several embryos were subjected to mechanic digestion. We re-suspended the cells in a Neurobasal medium with 2% B-27. We seeded in 48-well plates at a density of 100,000 cells/mL. Neuronal cultures were allowed to grow for 8–10 days. Incubations with different CSF were done when the microscope showed the existence of a dense neuronal network. Embryos were selected from 19 to 20 days pregnant rats, which were decapitated and embryos were extracted from the womb by caesarean section. Meninges were removed and a portion of motor cortex was isolated after the dissection of the brain. Fragments obtained from several embryos were subjected to mechanic digestion and cells were re-suspended in Neurobasal medium with 2% B-27 and seeded in 48-well plates at a density of 100,000 cells/mL. Neuronal cultures were allowed to grow for 8–10 days and when the microscope showed the existence of a dense neuronal network, incubations with different CSF were done [79].

3.3.2. Measurement of Neuronal Viability

We used the MTT reduction assay following the procedure previously described [65]. After the appropriate incubations with the compounds alone, or co-incubated with 100 µM H2O2 or glutamate, 0.5 mg/mL MTT were added to each well and incubation was performed at 37 °C for 2 h. Formazan salt formed was dissolved in DMSO, and colorimetric determination were performed at 540 nm. Control cells without compounds or toxic stimulus were considered 100% viability. Neuronal viability after exposure to compounds or different treatments was expressed as% of control within each individual experiment. Graph Pad Prism Software (GraphPad Software, San Diego, CA, USA) was used to perform statistical analyses and graphical presentation. Experiments were reproduced at least three times. Data were expressed as mean ± S.E.M. values. Groups were compared by ANOVA/Dunnett’s test. A p-value ≤0.05 was accepted as the limit of statistical significance.

4. Conclusions

We can use Shannon entropy measures to developing predictive models for multi-target networks of neuroprotective/neurotoxic compounds. In doing so, we can use Box–Jenkins operators of molecular descriptors to obtain multi-target, multi-scale, and multi-output models able to predict different outcomes for multiple combinations of output experimental measures, experimental protocols, organisms, and molecular and cellular targets. One of these models has been demonstrated here to be useful as a complementary tool in the organic synthesis and evaluation of the multi-target biological activity of new compounds with potential neuroprotective activity. The model is also a very useful tool to predict complex networks of drug-target interactions with possible applications to the study of non-linear effects in the biological activity of neuroprotective drugs.
Acknowledgments

The authors thank the Xunta de Galicia for financial support of this work under project 07CSA008203PR.

Author Contributions

Synthesis, identification, purification, and characterization of new organic compounds: Xerardo García-Mera, Olga Caamaño, and Nerea Alonso; Pharmacological assays: Matilde Yañez; Data retrieval and preprocessing, cheminformatics calculations, statistical analysis, complex network analysis, predictive study: Francisco J. Romero Durán, Francisco J. Prado-Prado and Humberto González-Díaz; Writing of paper: Francisco J. Romero Durán, Xerardo García-Mera, and Humberto González-Díaz.

Supplementary Information

Supplementary material files which contain detailed lists of the values of parameters are available upon requests to the corresponding author.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Mekenyan, O.; Bonchev, D.; Trinajstic, N. Chemical graph theory modeling the thermodynamic properties of molecules. *Intern. J. Quantum Chem. Symp.* **1980**, *18*, 369–380.
2. Bonchev, D.; Trinajstic, N. Information theory, distance matrix, and molecular branching. *J. Chem. Phys.* **1977**, *67*, 4517–4533.
3. Bonchev, D.; Kamenski, D.; Kamenska, V. Symmetry and information content of chemical structures. *Bull. Math. Biol.* **1976**, *38*, 119–133.
4. Kier, L.B. Use of molecular negentropy to encode structure governing biological activity. *J. Pharm. Sci.* **1980**, *69*, 807–810.
5. Stahura, F.L.; Godden, J.W.; Bajorath, J. Differential Shannon entropy analysis identifies molecular property descriptors that predict aqueous solubility of synthetic compounds with high accuracy in binary QSAR calculations. *J. Chem. Inf. Comput. Sci.* **2002**, *42*, 550–558.
6. Stahura, F.L.; Godden, J.W.; Xue, L.; Bajorath, J. Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. *J. Chem. Inf. Comput. Sci.* **2000**, *40*, 1245–1252.
7. Roy, K.; Saha, A. Comparative QSAR studies with molecular connectivity, molecular negentropy and tau indicespart I: Molecular thermochemical properties of diverse functional acyclic compounds. *J. Mol. Model.* **2003**, *9*, 259–270.
8. Agrawal, V.K.; Khadikar, P.V. Modelling of carbonic anhydrase inhibitory activity of sulfonamides using molecular negentropy. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 447–453.
9. Katritzky, A.R.; Lomaka, A.; Petrukhin, R.; Jain, R.; Karelson, M.; Visser, A.E.; Rogers, R.D. QSPR correlation of the melting point for pyridinium bromides, potential ionic liquids. *J. Chem. Inf. Comput. Sci.* **2002**, *42*, 71–74.

10. Katritzky, A.R.; Perumal, S.; Petrukhin, R.; Kleinpeter, E. Codessa-based theoretical QSPR model for hydantoin HPLC-RT lipophilicities. *J. Chem. Inf. Comput. Sci.* **2001**, *41*, 569–574.

11. Graham, D.J.; Schacht, D. Base information content in organic molecular formulae. *J. Chem. Inf. Comput. Sci.* **2000**, *40*, 942.

12. Graham, D.J. Information content in organic molecules: Structure considerations based on integer statistics. *J. Chem. Inf. Comput. Sci.* **2002**, *42*, 215.

13. Graham, D.J.; Malarkey, C.; Schulmerich, M.V. Information content in organic molecules: Quantification and statistical structure via brownian processing. *J. Chem. Inf. Comput. Sci.* **2004**, *44*, 1601–1611.

14. Graham, D.J.; Schulmerich, M.V. Information content in organic molecules: Reaction pathway analysis via brownian processing. *J. Chem. Inf. Comput. Sci.* **2004**, *44*, 1612–1622.

15. Graham, D.J. Information content and organic molecules: Aggregation states and solvent effects. *J. Chem. Inf. Model.* **2005**, *45*, 1223–1236.

16. Graham, D.J. Information content in organic molecules: Brownian processing at low levels. *J. Chem. Inf. Model.* **2007**, *47*, 376–389.

17. Strait, B.J.; Dewey, T.G. The Shannon information entropy of protein sequences. *Biophys. J.* **1996**, *71*, 148–155.

18. Dima, R.I.; Thirumalai, D. Proteins associated with diseases show enhanced sequence correlation between charged residues. *Bioinformatics* **2004**, *20*, 2345–2354.

19. Loewenstern, D.; Yianilos, P.N. Significantly lower entropy estimates for natural dna sequences. *J. Comput. Biol.* **1999**, *6*, 125–142.

20. Manke, T.; Demetrius, L.; Vingron, M. Lethality and entropy of protein interaction networks. *Genome Inform. Ser.* **2005**, *16*, 159–163.

21. Mikolas, P.; VyhnaneK, J.; Skoch, A.; Horacek, J. Analysis of FMRI time-series by entropy measures. *Neuro Endocrinol. Lett.* **2012**, *33*, 471–476.

22. Gonzalez-Diaz, H.; Duardo-Sanchez, A.; Ubeira, F.M.; Prado-Prado, F.; Perez-Montoto, L.G.; Concu, R.; Podda, G.; Shen, B. Review of march-inside & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. *Curr. Drug Metab.* **2010**, *11*, 379–406.

23. González-Díaz, H.; Molina, R.; Uriarte, E. Markov entropy backbone electrostatic descriptors for predicting proteins biological activity. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4691–4695.

24. González-Díaz, H.; de Armas, R.R.; Molina, R. Markovian negentropies in bioinformatics. 1. A picture of footprints after the interaction of the HIV-1 psi-RNA packaging region with drugs. *Bioinformatics* **2003**, *19*, 2079–2087.

25. Riera-Fernandez, P.; Munteanu, C.R.; Escobar, M.; Prado-Prado, F.; Martin-Romalde, R.; Pereira, D.; Villalba, K.; Duardo-Sanchez, A.; Gonzalez-Diaz, H. New Markov–Shannon entropy models to assess connectivity quality in complex networks: From molecular to cellular pathway, parasite-host, neural, industry, and legal-social networks. *J. Theor. Biol.* **2012**, *293*, 174–188.
26. Allegri, R.F.; Guekht, A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. In Drugs Today; 2012 Prous Science, S.A.U. or Its Licensors: Riva, MD, USA, 2012; Volume 48, pp. 25–41.
27. Park, N.H. Parkinson disease. JAAPA 2012, 25, 73–74.
28. Morris, H.R.; Waite, A.J.; Williams, N.M.; Neal, J.W.; Blake, D.J. Recent advances in the genetics of the ALS–FTLD complex. Curr. Neurol. Neurosci. Rep. 2012, 12, 243–250.
29. Trushina, E.; McMurray, C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007, 145, 1233–1248.
30. Martin, L.J. Biology of mitochondria in neurodegenerative diseases. In Progress in Molecular Biology and Translational Science; Elsevier Inc.: Amsterdam, The Netherlands, 2012; Volume 107, pp. 355–415.
31. Howells, D.W.; Sena, E.S.; O’Collins, V.; Macleod, M.R. Improving the efficiency of the development of drugs for stroke. Int. J. Stroke 2012, 7, 371–377.
32. Nurisso, A.; Simoes-Pires, C.; Martel, S.; Cressend, D.; Guillot, A.; Carrupt, P.A. How to increase the safety and efficacy of compounds against neurodegeneration? A multifunctional approach. Chimia 2012, 66, 286–290.
44. Speck-Planche, A.; Kleandrova, V.V.; Cordeiro, M.N. Chemoinformatics for rational discovery of safe antibacterial drugs: Simultaneous predictions of biological activity against streptococci and toxicological profiles in laboratory animals. *Bioorg. Med. Chem.* 2013, 21, 2727–2732.

45. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in multi-target drug discovery for anti-cancer therapy: *In silico* design of potent and versatile anti-brain tumor agents. *Anticancer Agents Med. Chem.* 2012, 12, 678–685.

46. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in anticancer chemotherapy: Multi-target QSAR model for the in silico discovery of anti-breast cancer agents. *Eur. J. Pharm. Sci.* 2012, 47, 273–279.

47. Vasaikar, S.V.; Padhi, A.K.; Jayaram, B.; Gomes, J. Neurodnet—An open source platform for constructing and analyzing neurodegenerative disease networks. *BMC NeuroSci.* 2013, 14, 3.

48. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target inhibitors for proteins associated with Alzheimer: *In silico* discovery using fragment-based descriptors. *Curr. Alzheimer Res.* 2013, 10, 117–124.

49. Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Role of ligand-based drug design methodologies toward the discovery of new anti-Alzheimer agents: Futures perspectives in fragment-based ligand design. *Curr. Med. Chem.* 2012, 19, 1635–1645.

50. Marzaro, G.; Chilin, A.; Guiotto, A.; Uriarte, E.; Brun, P.; Castagliuolo, I.; Tonus, F.; Gonzalez-Diaz, H. Using the tops-mode approach to fit multi-target QSAR models for tyrosine kinases inhibitors. *Eur. J. Med. Chem.* 2011, 46, 2185–2192.

51. Luan, F.; Cordeiro, M.N.; Alonso, N.; Garcia-Mera, X.; Caamano, O.; Romero-Duran, F.J.; Yanez, M.; Gonzalez-Diaz, H. Tops-mode model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. *Bioorg. Med. Chem.* 2013, 21, 1870–1879.

52. Alonso, N.; Caamano, O.; Romero-Duran, F.J.; Luan, F.; Dias Soeiro Cordeiro, M.N.; Yanez, M.; Gonzalez-Diaz, H.; Garcia-Mera, X. Model for high-throughput screening of multi-target drugs in chemical neurosciences; synthesis, assay and theoretic study of rasagiline carbamates. *ACS Chem. NeuroSci.* 2013, 4, 1393–1403.

53. Gerets, H.H.; Dhalluin, S.; Atienzar, F.A. Multiplexing cell viability assays. *Methods Mol. Biol.* 2011, 740, 91–101.

54. Hill, T.; Lewicki, P. *Statistics Methods and Applications. A Comprehensive Reference for Science, Industry and Data Mining*; StatSoft: Tulsa, OK, USA, 2006; Volume 1, p. 813.

55. Patankar, S.J.; Jurs, P.C. Classification of inhibitors of protein tyrosine phosphatase 1b using molecular structure based descriptors. *J. Chem. Inf. Comput. Sci.* 2003, 43, 885–899.

56. Garcia-Garcia, A.; Galvez, J.; de Julian-Ortiz, J.V.; Garcia-Domenech, R.; Munoz, C.; Guna, R.; Borras, R. New agents active against mycobacterium avium complex selected by molecular topology: A virtual screening method. *J. Antimicrob. Chemother.* 2004, 53, 65–73.

57. Marrero-Ponce, Y.; Castillo-Garit, J.A.; Olazabal, E.; Serrano, H.S.; Morales, A.; Castanedo, N.; Ibarra-Velarde, F.; Huesca-Guillen, A.; Sanchez, A.M.; Torrens, F.; *et al.* Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: Theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. *Bioorg. Med. Chem.* 2005, 13, 1005–1020.
58. Casanova-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Ather, A.; Sultan, S.; Torrens, F.; Rotondo, R. Tomocomd-cardd descriptors-based virtual screening of tyrosinase inhibitors: Evaluation of different classification model combinations using bond-based linear indices. *Bioorg. Med. Chem. 2007*, 15, 1483–1503.

59. Casanova-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Khan, S.B.; Torrens, F.; Perez-Jimenez, F.; Rescigno, A.; Abad, C. Bond-based 2D quadratic fingerprints in QSAR studies: Virtual and *in vitro* tyrosinase inhibitory activity elucidation. *Chem. Biol. Drug Des. 2010*, 76, 538–545.

60. Csermely, P.; Nussinov, R.; Szilagyi, A. From allosteric drugs to allo-network drugs: State of the art and trends of design, synthesis and computational methods. *Cur. Topics Med. Chem. 2013*, 13, 2–4.

61. Mueller, R.; Rodriguez, A.L.; Dawson, E.S.; Butkiewicz, M.; Nguyen, T.T.; Oleszkiewicz, S.; Bleckmann, A.; Weaver, C.D.; Lindsley, C.W.; Conn, P.J.; et al. Identification of metabotropic glutamate receptor subtype 5 potentiators using virtual high-throughput screening. *ACS Chem. NeuroSci. 2010*, 1, 288–305.

62. Szilagyi, A.; Nussinov, R.; Csermely, P. Allo-network drugs: Extension of the allosteric drug concept to protein–protein interaction and signaling networks. *Curr. Top. Med. Chem. 2013*, 13, 64–77.

63. Junker, B.H.; Koschutzki, D.; Schreiber, F. Exploration of biological network centralities with centibin. *BMC Bioinform. 2006*, 7, 219.

64. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; et al. Novel dual inhibitors of ache and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease. *J. Med. Chem. 2002*, 45, 5260–5279.

65. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods 1983*, 65, 55–63.

66. Fakhfouri, G.; Rahimian, R.; Ghia, J.E.; Khan, W.I.; Dehpour, A.R. Impact of 5-ht(3) receptor antagonists on peripheral and central diseases. *Drug Discov. Today 2012*, 17, 741–747.

67. Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M.B. Mechanism of neuroprotective action of the anti-parkinson drug rasagiline and its derivatives. *Brain Res. Brain Res. Rev 2005*, 48, 379–387.

68. Naoi, M.; Maruyama, W.; Inaba-Hasegawa, K. Revelation in the neuroprotective functions of rasagiline and selegiline: The induction of distinct genes by different mechanisms. *Expert Rev. Neurother. 2013*, 13, 671–684.

69. Fernandes, C.; Reddy, P.; Kessel, B. Rasagiline-induced serotonin syndrome. *Mov. Disord. 2011*, 26, 766–767.

70. Iwamoto, K.; Mata, D.; Linn, D.M.; Linn, C.L. Neuroprotection of rat retinal ganglion cells mediated through a7 nicotinic acetylcholine receptors. *Neuroscience 2013*, 237, 184–198.

71. Pera, M.; Camps, P.; Munoz-Torrello, D.; Perez, B.; Badia, A.; Clos Guillen, M.V. Undifferentiated and differentiated pc12 cells protected by huprines against injury induced by hydrogen peroxide. *PLoS One 2013*, 8, e74344.
72. Nuritova, F.; Frenguelli, B.G. Putative depolarisation-induced retrograde signalling accelerates the repeated hypoxic depression of excitatory synaptic transmission in area cal of rat hippocampus via group i metabotropic glutamate receptors. In *Neuroscience*, 2012 *IBRO*; Elsevier Ltd.: Waltham, MA, USA, 2012; Volume 222, pp. 159–172.

73. Sharma, H.S. A combination of tumor necrosis factor-α and neuronal nitric oxide synthase antibodies applied topically over the traumatized spinal cord enhances neuroprotection and functional recovery in the rat. *Ann. N. Y. Acad. Sci.* 2010, 1199, 175–185.

74. Drury, P.P.; Davidson, J.O.; van den Heuij, L.G.; Tan, S.; Silverman, R.B.; Ji, H.; Blood, A.B.; Fraser, M.; Bennet, L.; Gunn, A.J. Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. *Exp. Neurol.* 2013, 250, 282–292.

75. Concu, R.; Dea-Ayuela, M.A.; Perez-Montoto, L.G.; Prado-Prado, F.J.; Uriarte, E.; Bolas-Fernandez, F.; Podda, G.; Pazos, A.; Munteanu, C.R.; Ubeira, F.M.; et al. 3D entropy and moments prediction of enzyme classes and experimental–theoretic study of peptide fingerprints in leishmania parasites. *Biochim. Biophys. Acta* 2009, 1794, 1784–1794.

76. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target drug discovery in anti-cancer therapy: Fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. *Bioorg. Med. Chem.* 2011, 19, 6239–6244.

77. Tenorio-Borroto, E.; Penuelas Rivas, C.G.; Vasquez Chagoyan, J.C.; Castanedo, N.; Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Ann multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. *Bioorg. Med. Chem.* 2012, 20, 6181–6194.

78. Statistica (Data Analysis Software System), Version 6.0. Available online: http://www.statsoft.com (accessed on 2002).

79. Yanez, M.; Galan, L.; Matias-Guiu, J.; Vela, A.; Guerrero, A.; Garcia, A.G. Csf from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: Protection by resveratrol but not riluzole. In *Brain Research*; Elsevier B.V: Amsterdam, The Netherlands, 2011; Volume 1423, pp. 77–86.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).